COMPANY

Cilcare

HQ: Lexington, MA (US office) source · cilcare.com ↗

Keywords: neurology hearing inflammatory diseases Cochlear Synaptopathy Bilateral Tinnitus Mild Cognitive Impairment (MCI) Amnestic Parkinson Disease paliroden (CIL001) CIL001 (Paliroden)

Location: Lexington, MA (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Raises and deals from press releases

Deal Deal · amount not disclosed · announced Jun 23, 2026 Company release ↗
Source quote
- Jun 23, 2026 · Company release ↗
  “Montpellier, France, Paris, France and Boston, USA – June 23, 2026 – Cilcare, a biotechnology company focused on developing novel therapies for hearing disorders, announces an update of its license agreement covering its two lead programs, CIL001 and CIL003, on improved financial terms, alongside”

From the company’s own releases; this list is partial. All raises and deals

Timeline

Mar 24, 2025 Trial start Not phased (device or behavioral study): Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR) source ↗
2027-01 Trial start Phase 1/Phase 2: A Study Testing Safety and Efficacy of Transtympanic Paliroden for the Treatment of Cochlear Synaptopathy in Participants With Chronic, Constant Tinnitus source ↗
2026-08 Trial start Phase 1/Phase 2: A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Sit source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Not phased · Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR) · NCT07083089
2027-07 (ESTIMATED) · Phase 1/Phase 2 · A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Situations · NCT07472907
2028-01 (ESTIMATED) · Phase 1/Phase 2 · A Study Testing Safety and Efficacy of Transtympanic Paliroden for the Treatment of Cochlear Synaptopathy in Participants With Chronic, Constant Tinnitus · NCT07826507

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07826507	A Study Testing Safety and Efficacy of Transtympanic Paliroden for the Treatment of Cochlear Synaptopathy in Participants With Chronic, Constant Tinnitus	Phase 1/Phase 2	Not yet recruiting	2027-01	2028-01 (estimated)
NCT07472907	A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Situations	Phase 1/Phase 2	Not yet recruiting	2026-08	2027-07 (estimated)
NCT07083089	Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR)	Not phased (device or behavioral study)	Recruiting	Mar 24, 2025	2026-12 (estimated)